|
|
|
Shaping the Future of Women's Health with Innovations in Reproductive and Breast Cancer Research
Host: UCI Anti-Cancer Challenge
1:00 - 2:00 PM
Virtual Webinar
Learn More or Join via Zoom
| | | |
|
|
Surgical Advancements and New Therapies for Melanoma, Skin Cancer Prevention & Early Detection
Host: UCI Anti-Cancer Challenge
1:00 - 2:00 PM
Virtual Webinar
Learn More or Join via Zoom
| | | |
|
|
Community - Academic Partnered Research Presentations
Host: Institute for Clinical & Translational Science
2:00 - 3:30 PM
Virtual Presentations
Register for Zoom Link
| | | |
|
|
Research in Progress Seminar: Targeting Metabolic Support and Resistance Networks in Pancreatic Cancer
Speaker: Christopher Halbrook, PhD
12:00 - 1:00 PM
Virtual Webinar
Request a Calendar Invite or Join via Zoom
| | | |
|
|
Cancer Center Scientific Retreat
8:00 AM - 6:00 PM
Hyatt Regency Huntington Beach
Register Here
| | |
|
UCI Anti-Cancer Challenge Raises Over $1 Million in 2022 to Fund 28 Research Grants
Through the unwavering support of dedicated participants, donors, and supporters who collectively raised more than $1 million in 2022, the UCI Anti-Cancer Challenge has awarded grants to 28 pilot projects and early phase clinical trials, reaching a remarkable milestone of 100 funded projects since 2017. These projects are poised to revolutionize the future of cancer diagnosis, treatment, and cures. We invite you to learn more about the 2022 awardees and their funded projects. You can also read the press release here.
| |
|
New resources available for “Using Population Descriptors in Genetics and Genomics Research”
The National Academies report, “Using Population Descriptors in Genetics and Genomics Research: A New Framework for an Evolving Field,” released in March 2023, reviews and assesses existing methodologies, benefits, and challenges in using race, ethnicity, ancestry, and other population descriptors in genomics research. Here is a compilation of resources accompanying the report, including a Highlights document, a new animated video explaining a critical report graphic, and an interactive web page outlining key concepts from the report.
| |
|
We are pleased to announce that the Publication Rebate Program has been extended through 2023!
CFCCC is offering a $250 rebate towards publication costs for manuscripts that: (1) are cancer-related, (2) are accepted for publication in a peer-reviewed journal between April 1, 2019 and December 31, 2023, (3) appropriately acknowledge a CFCCC-supported Shared Resource, and (4) cite the P30CA062203 Cancer Center Support Grant. Please submit your publication for this rebate program through this link.
Please join us in congratulating the following Cancer Center members for their recent cancer-relevant publications and successful utilization of the Publication Rebate Program.
| |
| Name | Publication Title & Shared Resource(s) Used | | Farouk Nouizi, PhD
(Biotechnology, Imaging & Drug Development) | Acknowledged use of In Vivo Functional Onco-Imaging Shared Resource.
Development of a theranostic preclinical fluorescence molecular tomography/cone beam CT-guided irradiator platform (Biomedical Optics Express).
Development of a preclinical CCD-based temperature modulated fluorescence tomography platform (Biomedical Optics Express). | | Ling Gao, PhD
(Biotechnology, Imaging & Drug Development) | Acknowledged use of Optical Biology Core - Flow Cytometry Facility.
Selective Inhibition of Aurora Kinase A by AK-01/LY3295668 Attenuates MCC Tumor Growth by Inducing MCC Cell Cycle Arrest and Apoptosis (Cancers). | | |
|
Biostatistics Shared Resource - In-person Walk-in or Zoom Consultations Now Available
Informal statistical in-person walk-in or via Zoom consultations are available to discuss your study design and statistical needs. After you have booked the meeting, the Zoom information will be sent to you if you would like to meet via Zoom. Please note that walk-in services will not be available June 12 - July 1.
Questions? Contact Wen-pin Chen, Senior Statistician and BSR Manager.
| |
|
LIMITED SUBMISSION OPPORTUNITIES
Some opportunities limit the number of applications received from an institution. These limited submission opportunities require prior review and selection by the Cancer Center before the candidate can submit their full application to the awarding foundation. Submit the required documents to CFCCC Administration via the link provided by the internal deadline.
| |
|
(NEW) 2023 Gabrielle's Angel Foundation Medical Research Awards
Focus: Blood-related cancers
Limited Submission (2 nominees - junior faculty)
$225K/3 years
Pre-Application: July 24, 2023
Learn More and Apply >>
| |
|
OTHER NON-FEDERAL FUNDING OPPORTUNITIES
These opportunities do not require nomination or selection by the Cancer Center.
| |
|
Prevent Cancer Foundation Research Grants & Fellowships
$100K/2 years
Focus: Innovative research in cancer prevention and early detection
Proposal Due: July 11, 2023
Learn More and Apply >>
California Breast Cancer Research Program (CBCRP)
Convener on Fertility Preservation for Young Breast Cancer Patients
$40K/6 months
Application: August 2, 2023
Learn More and Apply >>
| |  |
|
California Breast Cancer Research Program (CBCRP)
Shift Work and Breast Cancer Risk
$300K (Project 1); $350K (Project 2)/2 years
Application: August 2, 2023
Learn More and Apply >>
Minnesota Ovarian Cancer Alliance (MOCA)
2023 National Early Detection of Ovarian Cancer Research Awards
$150K/1 year
Focus: early detection of ovarian, primary peritoneal, or fallopian tube cancer
Proposal: September 1, 2023
Learn More and Apply >>
| |
FEDERAL FUNDING OPPORTUNITIES | |
|
(NEW) Health Equity Leadership Development Initiative (MPI-CPI-23-001)
U.S Department of Health and Human Services - Office of Minority Health
$2 million/3 years
Focus: Implementation of a fellowship program
Applicant webinar: July 6, 2023 (12 pm PT) - Register here
Application: August 1, 2023
Learn More and Apply >>
*Please notify CFCCC Administration if you decide to participate
Congressionally Directed Medical Research Programs
FY23 Breast Cancer Research Program (BCRP) - next deadline June 29, 2023
FY23 Kidney Cancer Research Program (KCRP) - earliest deadline July 20, 2023
FY23 Lung Cancer Research Program (LCRP): Patient-Centered Outcomes and Survivorship Award (PCOSA) – July 20, 2023
FY23 Melanoma Research Program (MRP) - earliest deadline July 10, 2023
FY23 Pancreatic Cancer Research Program (PCARP) - earliest deadline July 10, 2023
FY23 Peer Reviewed Cancer Research Program (PRCRP) – next deadline July 25, 2023
FY23 Prostate Cancer Research Program (PCRP) – next deadline June 29, 2023
FY23 Rare Cancers Research Program (RCRP) - next deadline July 14, 2023
|
| |
|
|
UCI Health Named One of America's Best Cancer Hospitals by Newsweek
UCI Health has been recognized as one of America’s Best Cancer Hospitals by Newsweek in its inaugural rankings of the specialty, highlighting our commitment to exceptional cancer care. The UCI Health Chao Family Comprehensive Cancer Center is one of only 53 centers designated as comprehensive by the National Cancer Institute (NCI) and the only one in Orange County.
Read More >>
| | |
|
|
Breakthroughs Offer Hope for Vitiligo Patients
In 2018, Dr. Anand K. Ganesan opened a vitiligo specialty practice lab at the UCI Health Beckman Laser Institute & Medical Clinic, hoping to find new therapies to reverse the disfiguring skin disorder. Now, the lab has produced a topical cream called ruxolitinib, the first therapy approved by the U.S. Federal Drug Administration that restores pigment in vitiligo patients. The FDA also recently gave breakthrough device approval for RECELL®, a one-time therapy using the patient’s healthy cells to stimulate lasting repigmentation in stable vitiligo.
Read More >>
| | |
|
|
FDA Approves New Drug Combo for Prostate Cancer
Alexandre Chan, PharmD, MPH, professor of clinical pharmacy at the School of Pharmacy & Pharmaceutical Sciences at UCI is similarly excited about the prospect of this combination of medications being better understood and implemented. “I think that’s good news for patients, in the sense that there are additional therapies that we can use at first line and [they] have demonstrated that if you have the proper mutations, you get much better progression free and also overall survival.”
Read More >>
| | |
|
|
Adjusting Your Body Clock May Stave Off Cancer
For some time now epidemiological studies of night-shift workers have linked disruptions in circadian rhythms to cancer and other diseases. … “We're starting to understand the reasons these things happen,” says Selma Masri, a circadian biologist and assistant professor at UCI, who has shown how circadian disruption pushes colon cancer progression by interfering with the way certain genes are expressed.
Read More >>
| | |
|
|
The Audley Fund of the Philadelphia Foundation backs Dr. Daniela Bota's Search for a Glioblastoma Cure
UCI Health and neuro-oncologist Dr. Daniela A. Bota, MD are pleased to receive a third consecutive grant from The Audley Fund of the Philadelphia Foundation to support research to find a cure for brain cancer, especially glioblastoma. The award and the foundation’s continuing support reflects the deep need for basic science and clinical research into new treatments for glioblastoma, a deadly form of brain cancer with no cure.
Read More >>
| | | | |
